

Listing of Claims:

1. (previously presented) A composition comprising an agent effective to elicit an immunogenic response to alpha-synuclein and an adjuvant that is pharmaceutically acceptable for human administration, wherein the adjuvant is selected from the group consisting of QS21, monophosphoryl lipid, alum, CpG, GM-CSF and M-CSF, wherein the agent is alpha-synuclein or an immunogenic fragment thereof.

2. (canceled)

3. (previously presented) The composition of claim 1, wherein the agent is alpha-synuclein.

4. (previously presented) The composition of claim 1, wherein the agent is immunogenic alpha-synuclein fragment.

5. (previously presented) The composition of claim 4, wherein the agent is NAC.

6. (previously presented) The composition of any one of claims 1 or 3 - 5, wherein the agent is linked to a carrier molecule to form a conjugate.

7-53. (canceled)

54. (previously presented) The composition of claim 1, manufactured under good manufacturing practice conditions.

55. (previously presented) The composition of claim 1, wherein the agent is filter sterilized.